GRI Bio Reports Phase 2a IPF Drug Data for GRI-0621

GRI Bio reported positive Phase 2a topline and translational biomarker data for its oral idiopathic pulmonary fibrosis drug candidate, GRI-0621, showing safety, favorable tolerability, and a distinct tissue repair phenotype across multiple measurement modalities.

"What is emerging from the Phase 2a dataset is a profile we believe is unique among IPF programs," according to a statement published by BioPharmaWatch.

Study Design and Patient Cohort

The Phase 2a trial evaluated GRI-0621, an oral formulation of tazarotene, in 35 patients diagnosed with idiopathic pulmonary fibrosis, according to an Investing.com report. Participants were randomized in a 2:1 ratio to receive either 4.5 milligrams once daily of GRI-0621 or a placebo for a 12-week treatment period. Out of the total study population, 80% of patients received background standard-of-care therapy, specifically either pirfenidone or nintedanib.

Idiopathic pulmonary fibrosis is a chronic and progressive lung disease characterized by the scarring of lung tissue, which progressively impairs breathing and reduces functional vital capacity. Existing therapies aim to slow disease progression, but novel mechanisms targeting tissue repair remain a key focus of ongoing clinical research.

Safety and Tolerability Results

The clinical trial met its primary safety endpoint. According to company disclosures, GRI-0621 demonstrated favorable tolerability throughout the 12 weeks, with no drug-related severe or serious adverse events reported. Additionally, the trial observed no increase in gastrointestinal issues or cough relative to the placebo arm.

Functional Endpoint Measures

Beyond safety, the study evaluated exploratory functional endpoints including forced vital capacity, a standard physiological metric for assessing lung function.

At the conclusion of the 12-week period, 39% of patients treated with GRI-0621 experienced an FVC increase of at least 30 milliliters, compared with 20% of patients receiving the placebo. The trial recorded an overall placebo-adjusted FVC change from baseline of positive 99 milliliters, which increased to a positive 139 milliliters among patients receiving GRI-0621 alongside background standard-of-care therapy.